PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “FRAMYCETIN”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1987

Fucithalmic in acute conjunctivitis. Open, randomized comparison of fusidic acid, chloramphenicol and framycetin eye drops.

Fucithalmic, which is 1% fusidic acid in a sustained-release eye preparation, was shown to be superior to both chloramphenicol eye drops and framycetin (Soframycin) eye drops in the treatment of bacterial conjunctivitis in Tanzania. The clinical success rate was 77/83 (93%) on fusidic acid compared with 22/46 (48% on chloramphenicol and 26/35 (74%) on framycetin (P less than or equal to 0.02). The better effect of fusidic acid could be ascribed to a much lower rate of in vitro resistance (17%) compared to chloramphenicol (58%) and framycetin (41%). Because of the low resistance rate to fusidic acid among eye pathogens, especially in areas of the world with a high resistance towards other commonly used eye anti-infectives, Fucithalmic given twice daily would seem to be a valuable new eye anti-infective.

Acute Disease↗
PubMedDate not supplied

[Bilateral deafness due to the local use of framycetin (author's transl)].

A case is reported of total bilateral cochleo-vestibular destruction following instillation of Framycetin into the middle ear, under pressure, through a transtympanic drain. Toxicity of Framycetin after local use is exceptional and only one case, reported by Ransome, was found in the published literature. The interest of this observation is that, by using puncture of the foot of the stapes, it was possible to find Framycetin in the perilymphatic liquid three weeks after the injection of the product.

Administration, Topical↗
PubMed1987

Laboratory evaluation of topically used antibiotics: framycetin MIC and extinction time data for Pseudomonas aeruginosa.

Minimum inhibitory concentration (MIC) and extinction time (ET) of framycetin (0.5% in isotonic buffer) were determined. Of 90 consecutive clinical isolates of Pseudomonas aeruginosa, obtained from patients with ear or eye infections, 88.9% were inhibited by 62.5 mg/l and 96.66% were killed within 60 min by framycetin (0.5%). Determination of ET appears to be a promising technique for quantifying the bacterial action of high drug concentrations. Further clinical and experimental studies are required to see whether the ET predicts the efficacy of topical antibacterial preparations better than the MIC.

Administration, Topical↗
PubMed1976

Incidence of neomycin and framycetin sensitivity.

A total of 450 consecutive patients were patch-tested to both neomycin and framycetin (20% in petrolatum). Thirteen patients were sensitive to both preparations, 10 to neomycin alone and four to framycetin alone. The significance of these results is discussed, with particular reference to the constituents of the preparations and the allergenic groups involved.

Dermatitis, Contact↗
PubMed2001

[Optimization of aerosol therapy in otorhinolaryngology: stability and granulometry of dexamethasone-gomenol-framycetin solution].

Nebulization of solutions associating gomenol, dexamethasone and framycetin is very widespread in otorhinolaryngology (particularly for the treatment of actue laryngitis and post-traumatic laryngitis and rhinitis and for the tracheotomy care). A rigorous clinical evaluation is however lacking. The aim of this work was to evaluate use of such solutions in comparison with the recommendations issuing from the National Session in April 1997 on good practices for aerosol therapeutics. Stability and granulometry were studied in order to optimize processing. A new formulation and new technical methods of administration are proposed in relation to the results of this study and the national recommendations.

Aerosols↗